Jennifer Schmitke
Direttore operativo presso IMV INC.
Profilo
Jennifer Schmitke is currently the Chief Operating Officer at IMV, Inc. She previously worked as a Senior Director at Biogen, Inc., SVP-Technical Operations & Quality at Epizyme, Inc., Vice President & Head-Program Management at Magenta Therapeutics, Inc., and Vice President at Omega Therapeutics, Inc. Schmitke received an undergraduate degree from Queen's University and a doctorate degree from Massachusetts Institute of Technology.
Posizioni attive di Jennifer Schmitke
| Società | Posizione | Inizio |
|---|---|---|
| IMV INC. | Direttore operativo | - |
Precedenti posizioni note di Jennifer Schmitke
| Società | Posizione | Fine |
|---|---|---|
| EPIZYME, INC. | Corporate Officer/Principal | 01/04/2022 |
| BIOGEN INC. | Direttore/Membro del Consiglio | - |
| OMEGA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| MAGENTA THERAPEUTICS | Corporate Officer/Principal | - |
Formazione di Jennifer Schmitke
| Queen's University | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| OMEGA THERAPEUTICS, INC. | Health Technology |
| IMV INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Jennifer Schmitke
